REVISOR

13-2059

This Document can be made available in alternative formats upon request

State of Minnesota

HOUSE OF REPRESENTATIVES EIGHTY-EIGHTH SESSION H. F. No. 1045

| 02/28/2013 | Authored by Mahoney, Rosenthal, Davids, Daudt and Uglem |
|------------|--|
| | The bill was read for the first time and referred to the Committee on Jobs and Economic Development Finance and Policy |
| 04/04/2013 | Adoption of Report: Pass and re-referred to the Committee on Taxes |
| | Pursuant to Joint Rule 2.03, re-referred to the Committee on Rules and Legislative Administration |
| | |

| 1.1 1.2 1.3 1.4 1.5 | A bill for an act relating to economic development; establishing a technology corporate franchise tax certificate transfer program; amending Minnesota Statutes 2012, sections 290.01, subdivision 29; 290.06, by adding a subdivision; proposing coding for new law in Minnesota Statutes, chapter 116J. |
|---------------------------------|---|
| 1.6 | BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA: |
| 1.7 | Section 1. [116J.8738] TECHNOLOGY CORPORATE FRANCHISE TAX |
| 1.8 | CERTIFICATE TRANSFER PROGRAM. |
| 1.9 | Subdivision 1. Program established. The commissioner shall establish a corporate |
| 1.10 | franchise tax benefit certificate transfer program to allow new or expanding emerging |
| 1.11 | technology and biotechnology companies in this state with unused net operating loss |
| 1.12 | carryovers under section 290.095 to surrender those tax benefits for use by other corporate |
| 1.13 | franchise taxpayers in this state. The tax benefits may be used on the corporate franchise |
| 1.14 | tax returns to be filed by those taxpayers in exchange for private financial assistance to |
| 1.15 | be provided by the corporate franchise taxpayer that is the recipient of the tax benefit |
| 1.16 | certificate to assist in the funding of costs incurred by the new or expanding emerging |
| 1.17 | technology and biotechnology company. |
| 1.18 | Subd. 2. Definitions. (a) For purposes of this section, the following terms have the |
| 1.19 | meanings given, unless the context clearly requires otherwise. |
| 1.20 | (b) "Biotechnology" means the continually expanding body of fundamental |
| 1.21 | knowledge about the functioning of biological systems from the macro level to the |
| 1.22 | molecular and subatomic levels, as well as novel products, services, technologies, and |
| 1.23 | sub-technologies developed as a result of insights gained from research advances that add |
| 1.24 | to that body of fundamental knowledge. |
| 1.25 | (c) "Biotechnology company" means an emerging corporation that: |
| | |

1

REVISOR

13-2059

| 2.1 | (1) has its headquarters or base of operations in this state; |
|------|--|
| 2.2 | (2) owns, has filed for, or has a valid license to use protected, proprietary intellectual |
| 2.3 | property; and |
| 2.4 | (3) is engaged in the research, development, production, or provision of |
| 2.5 | biotechnology for the purpose of developing or providing products or processes |
| 2.6 | for specific commercial or public purposes, including but not limited to, medical, |
| 2.7 | pharmaceutical, nutritional, and other health-related purposes, agricultural purposes, and |
| 2.8 | environmental purposes. |
| 2.9 | (d) "Full-time employee" means a person employed by a new or expanding emerging |
| 2.10 | technology or biotechnology company for consideration for at least 35 hours a week, or |
| 2.11 | who renders any other standard of service generally accepted by custom or practice as |
| 2.12 | full-time employment and whose wages are subject to withholding as provided in section |
| 2.13 | 290.92, or who is a partner of a new or expanding emerging technology or biotechnology |
| 2.14 | company who works for the partnership for at least 35 hours a week, or who renders |
| 2.15 | any other standard of service generally accepted by custom or practice as full-time |
| 2.16 | employment, and whose distributive share of income, gain, loss, or deduction, or whose |
| 2.17 | guaranteed payments, or any combination thereof, is subject to the payment of estimated |
| 2.18 | taxes, as provided in section 289A.25. To qualify as a full-time employee, an employee |
| 2.19 | must also receive from the new or expanding emerging technology or biotechnology |
| 2.20 | company group health benefits under a health plan as defined under section 62A.011, |
| 2.21 | subdivision 3, or under a self-insured employee welfare benefit plan as defined in United |
| 2.22 | States Code, title 29, section 1002. Full-time employee excludes any person who works as |
| 2.23 | an independent contractor or on a consulting basis for the new or expanding emerging |
| 2.24 | technology or biotechnology company. |
| 2.25 | (e) "New or expanding" means a technology or biotechnology company that: |
| 2.26 | (1) on June 30 of the year in which the corporation files an application for surrender |
| 2.27 | of unused but otherwise allowable tax benefits under this section and on the date of the |
| 2.28 | exchange of the corporate franchise tax benefit certificate, has fewer than 250 employees |
| 2.29 | in the United States; |
| 2.30 | (2) on June 30 of the year in which the corporation files the application, has at least |
| 2.31 | one full-time employee working in this state if the company has been incorporated for less |
| 2.32 | than three years, has at least five full-time employees working in this state if the company |
| 2.33 | has been incorporated for more than three years but less than five years, and has at least |
| 2.34 | ten full-time employees working in this state if the company has been incorporated for |
| 2.35 | more than five years; and |

2

SS/AF

| 3.1 | (3) on the date of the exchange of the corporate franchise tax benefit certificate, the |
|------|--|
| 3.2 | corporation has the number of full-time employees in this state required by clause (2). |
| 3.3 | (f) "Technology company" means an emerging corporation that: |
| 3.4 | (1) has its headquarters or base of operations in this state; |
| 3.5 | (2) owns, has filed for, or has a valid license to use protected, proprietary intellectual |
| 3.6 | property; and |
| 3.7 | (3) employs some combination of the following: highly educated or trained |
| 3.8 | managers and workers, or both, employed in this state who use sophisticated scientific |
| 3.9 | research service or production equipment, processes, or knowledge to discover, develop, |
| 3.10 | test, transfer, or manufacture a product or service. |
| 3.11 | Subd. 3. Allocation of tax benefits; annual limit. (a) The commissioner, in |
| 3.12 | cooperation with the commissioner of revenue, shall review and approve applications by |
| 3.13 | new or expanding emerging technology and biotechnology companies in this state with |
| 3.14 | unused but otherwise allowable net operating loss carryovers under section 290.095, to |
| 3.15 | surrender those tax benefits in exchange for private financial assistance to be made by the |
| 3.16 | corporate franchise taxpayer that is the recipient of the corporate franchise tax benefit |
| 3.17 | certificate in an amount equal to at least 75 percent of the amount of the surrendered tax |
| 3.18 | benefit. The amount of the surrendered tax benefit is the amount of the net operating loss |
| 3.19 | carryover multiplied by the new or expanding emerging technology or biotechnology |
| 3.20 | company's anticipated apportionment percentage, as determined under section 290.191, |
| 3.21 | for the taxable year in which the benefit is transferred and subsequently multiplied by the |
| 3.22 | corporate franchise tax rate under section 290.06, subdivision 1. |
| 3.23 | (b) The commissioner must approve the transfer of no more than \$60,000,000 of |
| 3.24 | tax benefits in each fiscal year. If the total amount of transferable tax benefits requested |
| 3.25 | to be surrendered by approved applicants exceeds \$60,000,000 for a fiscal year, the |
| 3.26 | commissioner, in cooperation with the commissioner of revenue, must not approve the |
| 3.27 | transfer of more than \$60,000,000 for that fiscal year and shall allocate the transfer of tax |
| 3.28 | benefits by approved corporations using the following method: |
| 3.29 | (1) an eligible applicant with \$250,000 or less of transferable tax benefits is |
| 3.30 | authorized to surrender the entire amount of its transferable tax benefits; |
| 3.31 | (2) an eligible applicant with more than \$250,000 of transferable tax benefits is |
| 3.32 | authorized to surrender a minimum of \$250,000 of its transferable tax benefits; and |
| 3.33 | (3) an eligible applicant with more than \$250,000 of transferable tax benefits is |
| 3.34 | authorized to surrender additional transferable tax benefits determined by multiplying |
| 3.35 | the applicant's transferable tax benefits less the minimum transferable tax benefits that |
| 3.36 | corporation is authorized to surrender under clause (2) by a fraction, the numerator of |

SS/AF

| 4.1 | which is the total amount of transferable tax benefits that the commissioner is authorized |
|------|---|
| 4.2 | to approve less the total amount of transferable tax benefits approved under clauses (1) |
| 4.3 | and (2) and the denominator of which is the total amount of transferable tax benefits |
| 4.4 | requested to be surrendered by all eligible applicants less the total amount of transferable |
| 4.5 | tax benefits approved under clauses (1) and (2). |
| 4.6 | (c) If the total amount of transferable tax benefits that would be authorized using the |
| 4.7 | method under paragraph (b) exceeds \$60,000,000 for a fiscal year, then the commissioner, |
| 4.8 | in cooperation with the commissioner of revenue, shall limit the total amount of tax |
| 4.9 | benefits authorized to be transferred to \$60,000,000 by applying the above method on an |
| 4.10 | apportioned basis. |
| 4.11 | Subd. 4. Qualifying tax benefits and corporations. For purposes of this section, |
| 4.12 | transferable tax benefits include an eligible applicant's unused but otherwise allowable |
| 4.13 | carryover of net operating losses multiplied by the applicant's anticipated allocation factor |
| 4.14 | as determined under section 290.191 for the taxable year in which the benefit is transferred |
| 4.15 | and subsequently multiplied by the corporation franchise tax rate under section 290.06, |
| 4.16 | subdivision 1. An eligible applicant's transferable tax benefits are limited to net operating |
| 4.17 | losses that the applicant requests to surrender in its application to the authority and must |
| 4.18 | not, in total, exceed the maximum amount of tax benefits that the applicant is eligible to |
| 4.19 | surrender. No application for a corporate franchise tax benefit transfer certificate must be |
| 4.20 | approved in which the new or expanding emerging technology or biotechnology company: |
| 4.21 | (1) has demonstrated positive net operating income in any of the two previous full |
| 4.22 | years of ongoing operations as determined on its financial statements issued according to |
| 4.23 | generally accepted accounting standards endorsed by the Financial Accounting Standards |
| 4.24 | Board; or |
| 4.25 | (2) is directly or indirectly at least 50 percent owned or controlled by another |
| 4.26 | corporation that has demonstrated positive net operating income in any of the two previous |
| 4.27 | full years of ongoing operations as determined on its financial statements issued according |
| 4.28 | to generally accepted accounting standards endorsed by the Financial Accounting |
| 4.29 | Standards Board or is part of a consolidated group of affiliated corporations, as filed for |
| 4.30 | federal income tax purposes, that in the aggregate has demonstrated positive net operating |
| 4.31 | income in any of the two previous full years of ongoing operations as determined on |
| 4.32 | its combined financial statements issued according to generally accepted accounting |
| 4.33 | standards endorsed by the Financial Accounting Standards Board. |
| 4.34 | The maximum lifetime value of surrendered tax benefits that a corporation is permitted to |
| 4.35 | surrender under the program is \$15,000,000. |
| | |

13-2059

| 5.1 | Subd. 5. Recapture of tax benefits. The commissioner, in consultation with the |
|------|--|
| 5.2 | commissioner of revenue, shall establish rules for the recapture of all, or a portion of, |
| 5.3 | the amount of a grant of a corporate franchise tax benefit certificate from the new or |
| 5.4 | expanding emerging technology or biotechnology company having surrendered tax |
| 5.5 | benefits under this section if the taxpayer fails to use the private financial assistance |
| 5.6 | received for the surrender of tax benefits as required by this section or fails to maintain a |
| 5.7 | headquarters or a base of operation in this state during the five years following receipt |
| 5.8 | of the private financial assistance; except if the failure to maintain a headquarters or a |
| 5.9 | base of operation in this state is due to the liquidation of the new or expanding emerging |
| 5.10 | technology or biotechnology company. |
| 5.11 | Subd. 6. Approval of acquisition of tax benefits; purposes; required agreement. |
| 5.12 | (a) The commissioner, in cooperation with the commissioner of revenue, shall review and |
| 5.13 | approve applications by taxpayers under the corporate franchise tax in chapter 290 to |
| 5.14 | acquire surrendered tax benefits approved under subdivision 3, which must be issued in |
| 5.15 | the form of corporate franchise tax benefit transfer certificates, in exchange for private |
| 5.16 | financial assistance to be made by the taxpayer in an amount equal to at least 75 percent of |
| 5.17 | the amount of the surrendered tax benefit of an emerging technology or biotechnology |
| 5.18 | company. The commissioner must not issue a corporate franchise tax benefit transfer |
| 5.19 | certificate, unless the applicant certifies that as of the date of the exchange of the corporate |
| 5.20 | franchise tax benefit certificate it is operating as a new or expanding emerging technology |
| 5.21 | or biotechnology company and has no current intention to cease operating as a new or |
| 5.22 | expanding emerging technology or biotechnology company. |
| 5.23 | (b) The private financial assistance shall assist in funding expenses incurred |
| 5.24 | in connection with the operation of the new or expanding emerging technology or |
| 5.25 | biotechnology company in this state, including but not limited to the expenses of fixed |
| 5.26 | assets, such as the construction and acquisition and development of real estate, materials, |
| 5.27 | start-up, tenant fit-out, working capital, salaries, research and development expenditures, |
| 5.28 | and any other expenses determined by the commissioner to be necessary to carry out |
| 5.29 | emerging technology or biotechnology company operations in this state. |
| 5.30 | (c) The commissioner shall require a corporate franchise taxpayer that acquires |
| 5.31 | a corporate franchise tax benefit certificate to enter into a written agreement with the |
| 5.32 | new or expanding emerging technology or biotechnology company concerning the terms |
| 5.33 | and conditions of the private financial assistance made in exchange for the certificate. |
| 5.34 | The written agreement may contain terms concerning the maintenance by the new or |
| 5.35 | expanding emerging technology or biotechnology company of a headquarters or a base |
| 5.36 | of operation in this state. |

5

| | 02/20/13 | REVISOR | SS/AF | 13-2059 | | |
|------|--|--------------------------|-----------------------|-----------|--|--|
| 6.1 | EFFECTIVE DATE. This section is effective the day following final enactment | | | | | |
| 6.2 | and applies to taxable years beginning after December 31, 2012. | | | | | |
| | | | | | | |
| 6.3 | Sec. 2. Minnesota Statutes 2012, sec | tion 290.01, subdivisio | n 29, is amended to | read: | | |
| 6.4 | Subd. 29. Taxable income. The term "taxable income" means: | | | | | |
| 6.5 | (1) for individuals, estates, and trusts, the same as taxable net income; | | | | | |
| 6.6 | (2) for corporations, the taxable net income less | | | | | |
| 6.7 | (i) the net operating loss deduction under section 290.095, excluding any amount | | | | | |
| 6.8 | surrendered under section 116J.8738; | | | | | |
| 6.9 | (ii) the dividends received deduction | on under section 290.2 | 1, subdivision 4; | | | |
| 6.10 | (iii) the exemption for operating i | n a job opportunity bui | lding zone under se | ction | | |
| 6.11 | 469.317; and | | | | | |
| 6.12 | (iv) the exemption for operating in | n a biotechnology and | health sciences indu | ıstry | | |
| 6.13 | zone under section 469.337. | | | | | |
| 6.14 | EFFECTIVE DATE. This sectio | n is effective for taxab | le years beginning a | ıfter | | |
| 6.15 | December 31, 2012. | | | | | |
| | | | | | | |
| 6.16 | Sec. 3. Minnesota Statutes 2012, sec | tion 290.06, is amende | d by adding a subdi | vision | | |
| 6.17 | to read: | | | | | |
| 6.18 | Subd. 36. Credit; technology co | rporate franchise tax | certificate transfe | <u>r.</u> | | |
| 6.19 | A taxpayer may take a credit against th | e tax imposed under su | bdivision 1 or secti | on | | |
| 6.20 | 290.0921 equal to the amount of the tra | nsferable tax benefits c | ertified to the taxpa | yer for | | |
| 6.21 | the taxable year by the commissioner of | f employment and econ | omic development | under | | |
| 6.22 | section 116J.8738. | | | | | |
| 6.23 | EFFECTIVE DATE. This section | n is effective for taxab | le years beginning a | ıfter | | |

6.24 December 31, 2012.